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Aim: This study sought to explore the exact mechanism of Matrine inhibited migration and invasion of human
pancreatic cancer cells.
Methods: HPAC or Capan-1 cells were cultured in completed RPMI-1640 medium, contained with 50 μg/ml Matrine
or 0.05 μg/ml docetaxel, respectively. Cell viability was evaluated by spectrophotometric analysis using MTT assay.
Wound healing assay and transwell approach were used to detect the effects of Matrine on HPAC cell migration
and invasion. Western Blot and RT-PCR were performed to detect the expressions of MT1-MMP, Wnt and β-Catenin.
CHIP assay was used to detect whether the MT1-MMP transcription activity correlated with Wnt signaling pathway.
Results: MTT results indicated that cell proliferration was inhibited by Matrine at a range of concentrations, especially
at high dose. We further found that Matrine treatment significantly induced cell migration and invasion decreased.
Interestingly, the expression of MT1-MMP decreased evidently upon Matrine treatment, paralleled with the expressions
of Wnt and β-Catenin detected by Western Blot and RT-PCR assay. Further analysis of MT1-MMP transcription activity
revealed that Matrine reduced the expression of MT1-MMP mediated by Wnt signaling pathway.
Conclusion: Matrine play a vital role in inhibiting HPAC cellular migration and invasion through down-regulating the
expression of MT1-MMP via Wnt signaling pathway.
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Matrine has been used for cancer treatment in China for
a long time, which was extracted from Chinese Medicine
plant. It was demonstrated that matrine was efficiency
and safety using in clinic. Previous researches reported
that Matrine has a role in inhibiting the growth of tumor
cells directly [1]. In clinical work it has been used for
treating the uterine cervical cancer and leukemia [2, 3].
Recently, some researchers suggest that matrine could
inhibit cancer cells migration, invasion and metastasis
[4–6]. But the exact molecular mechanism of matrine in
inhibiting cell adhesion and migration need further* Correspondence: wr0395@sina.com; lhyzmyc@126.com
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creativecommons.org/publicdomain/zero/1.0/study. It was important to make an intensive investiga-
tion of the pharmacologic and clinic applications of
matrine and maybe it could help researcher figure out
the mechanism of tumorigenesis in human.
Wnt signaling pathway play a vital role in normal de-
velopments but also in tumorigenesis [7]. Inappropriate
activation of Wnt signaling pathway results in the onset
of several types of canceres [8]. Based on the differences
of interactions with Wnt receptors or co-receptors, Wnt
signaling pathway has been divided into three signaling
pathways, namely the canonical Wnt/β-catenin, the non-
canonical (or heretical) Wnt/ Ca2+ and planar cell polar-
ity (PCP) pathways [9]. Previous researches suggested
that the Wnt/PCP pathway interaction with some key
proteines related with cell polarization, motility, cancer
cell migration and invasion [10, 11]. β-catenin involved
in the canonical Wnt pathway as a key mediator, whiche distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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factors Lef and Tcf, leading to the transcription of Wnt
target genes [12, 13]. The stabilization of β-catenin was
regulated by phosphorylated modification by GSK3β,
followed by degradation via the proteasome. Abnormal
activated Wnt/β-catenin pathway has been detected in a
number of human tumors including lung, breast, cervical
and liver, that is due to β-catenin lack of degradation and
ultimately nuclear accumulation. In hepatocellular car-
cinoma, β-catenin accumulation has been linked to
poorly differentiated, high proliferative activity and
poor prognosis [14, 15]. The level of β-catenin is regu-
lated by numerous proteins, which, if not regulated or
expressed appropriately would account for increased β-
catenin expression in cancer. By forming a complex
with Tcf-4, β-catenin activates the transcription of tar-
get genes included MT1-MMP, which correlates with
cancer cell migration and invasion [16].
Abnormal expression of MT1-MMP has been found
in many types of canceres. Such an induction expression
of MT1-MMP could be regulated by the Wnt/β-catenin
signaling pathway. This is based on the observation that
depletion of β-catenin in colorectal carcinoma SW480
cells resulting down-regulation expression of MT1-
MMP [17]. In the present study, our group has found
that in some concentration ranges, matrine has the ef-
fect of inhibiting the migration of pancreatic carcinoma
HPAC or Capanc-1 cells.
Materials and methods
Cell culture and experimental reagents
Human pancreatic cancer cells, such as HPAC, Capan-1
(from American Type Culture Collection, Rockville, MD)
were cultured in RPMI-1640 (Invitrogen) supplemented
with 10 % fetal bovine serum (FBS) and 100 units/mL peni-
cillin and 100 μg/mL streptomycin, in a 5 % CO2 humidi-
fied atmosphere at 37 °C. Matrine (50 μg/ml, Qilu
Pharmaceutical Co., Ltd.) and docetaxel (0.05 μg/ml, Sigma,
USA) were added into the medium when necessary as indi-
cated in figure legends. Primary antibodies of Wnt, β-
catenin, MT1-MMP, and β-actin were purchased from
Santa Cruz Biotechnology (Santa Cruz, USA). Other re-
agents used in this study, such as Anti-mouse-IgG-HRP
and Anti-Rabbit-IgG-HRP, were purchased from California
Bioscience (California Bioscience, USA), Transwell Invasion
Chambers were found from Promega, USA.
MTT assay
MTT [3-(4,5-dimethylthiazolyl-2-yl)-2,5-diphenyltetrazo-
lium bromide] (Sigma- Aldrich; St. Louis, MO) assay
was used for evaluation the viability of HPAC or Capan-
1 cells upon Matrine treatment. Total 1 × 104 cells/well
were grown overnight in 96-well plate. The second day,
various concentrations of Matrine were added andincubation for 48 h. MTT solution was added to each
well at a final concentration of 500 μg/ml for 4 h. For-
mazan crystals formed by living cells were then dissolved
in DMSO and measured at 570 nm by Multi-Detection
microplate reader (Bio-Rad, USA).
Monolayer cell migration assay
A monolayer wound-healing model was performed as cell
migration assay. HPAC or Capan-1 cells were seeded in 6-
well-plate for 24 h in RPMI-1640 medium. A confluent
monolayer of HPAC cells were then scraped with a sterile
200 μl pipette tip and washed with PBS. After incubation
with completed RPMI-1640 alone or contained with
matrine (50 μg/ml) or with docetaxel (0.05 μg/ml) for
48 h, cell migration images were captured using an
inverted phase contrast microscope at 100× magnification.
Transwell invasion assay
Matrigel Invasion Chambers were hydrated for 4 h be-
fore starting the invasion assay. Log-phase cells (4 × 104)
were plated in 200 μl RPMI-1640 containing 2 % FBS in
the upper chamber of the transwell. The lower chamber
was filled with 500 μl completed RPMI-1640 containing
10 % FBS. The upper chamber cells were treated with
matrine and docetaxel as previous description and
allowed to migrate for 10 h at 37 °C and 5 % CO2 cir-
cumstance followed by carrying out the invasion assay.
The cells were fixed for 15 min at room temperature by
replacing the culture medium in the bottom with 4 %
formaldehyde dissolved in PBS. Then, the cells on the
upper chamber were moved with a cotton swab. After
washing the chambers 5 times by dipping the chambers
in a large beaker filled with dH2O, the cells that
remained on the bottom of the lower chamber were
stained with 0.1 % crystal violet. The migrated clones
were photographed under an optical microscope. The
cell numbers were counted at 12 different areas.
RT–PCR analysis
Total RNA was extracted from HPAC cells using the TRI-
ZOL reagent (Invitrogen Life Technologies). Reverse tran-
scription (RT) was performed with 1 μg of total RNA and
10 μM of specific primers. cDNAs were amplified by poly-
merase chain reaction (PCR) for testing MT1-MMP (sense
5′-AGCCCCGAAGCCTGGCTACA-3′; antisense 5′-GC
CGCCCTCACCATCGAAGG-3′,492-bp product) and
Glyceral dehyde-3-phosphate dehydrogenase (GAPDH)
(sense 5′-ACCACAGTCCAT GCCATCAC-3′; antisense
5′-TCCACCACCCTGTTGCTGTA-3′, 556-bp product),
which was used as loading controls.
Enzyme-linked immunosorbent assay
HPAC cells were treated as described above. Concentra-
tions of MMP-9 and MMP-2 in the cell culture
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ELISA kits (R&D Systems, USA). Each sample was ana-
lysed in triplicate and manipulated according to the kit’s
protocols.
Western blot analysis
HPAC cells were lysed in RIPA buffer [50 mM Tris
(pH 7.4), 150 mM NaCl, 1 % Triton X-100, 0.1 % SDS,
1 % sodium deoxycholate, 5 mM EDTA, 100 mM NaF,
and 1 mM Na3VO4] containing a protease inhibitor
cocktail for 30 min on ice, followed by centrifuged for
30 min at 16000 g. Protein concentrations were deter-
mined by the BCA method (Pierce, USA). Equal total
proteins were electrophoresis by 12 % SDS-PAGE gel
and transferred to PVDF membranes using a wet trans-
blot system (Bio-Rad, Hercules, CA). The membranes
were blocked for 1 h at room temperature with 5 % non-
fat dry milk and incubated overnight at 4 °C with anti-
bodies against Wnt, β-catenin, Axin, GSK-3β, MT1-
MMP and β-actin (1:1000). After washing three times,
membrane was incubated for 1 h with HRP-conjugated
goat anti-rabbit secondary antibody diluted 1:5,000 in
PBST. After further washing and processed using Super
Signal West Pico chemiluminescent substrate (Pierce,
USA), the membrane was exposed to Fujifilm LAS3000
Imager (Fuji, Japan). The band densities were normalized
relative to the relevant β-actin with Image J Analyst soft-
ware (NIH).
Chromatine immuno-precipitation (CHIP) assay
CHIP assay was performed using the CHIP Kit (Sigma,
USA) with slight modifications. HPAC cells (2 × 107)
were cross-linked with 1 % formaldehyde for 10 min at
room temperature, followed by the addition of 1 ml of
125 mM glycine to inactivate the formaldehyde. Cells
were washed twice with ice-cold PBS and then scraped
and centrifuged at 1000 g at 4 °C for 5 min. Pelleted cells
were lysed with 1 ml modified-RIPA lysis buffer (0.1 %
SDS, 10 mM EDTA, 1 % Triton Χ-100 and 50 mM
Tris–HCl pH 8.0) containing with protease inhibitor
cocktail and incubated on ice for 10 min. After sonic-
ation to produce genomic DNA to lengths of 0.2 to
0.5 kb (optimized at 10 ~ 15-s pulses), samples were cen-
trifuged at 13,000 g for 10 min to remove insoluble cell
debris. Lysates were diluted in ChIP dilution buffer
(0.01 % SDS, 0.1 % Triton X-100, 2 mM EDTA, 20 mM
Tris–HCl pH 8.0 and 500 mM NaCl). Chromatin solu-
tion was precleared with 20 μl of 3 % BSA/protein A
agarose for 2 h at 4 °C with rotation. Anti–β-catenin
polyclonal (Santa Cruz Biotechnologies) antibody was
added to the precleared supernatant and incubated over-
night at 4 °C with rotation. Negative controls included a
sample incubated without antibody and one incubated
with rabbit IgG (Santa Cruz Biotechnologies) to determinewhether interactions were due to nonspecific IgG interac-
tions. Bead complexes were washed first with low-salt im-
mune complex wash buffer, followed by high-salt immune
complex wash buffer and a final LiCl immune complex
wash buffer for 5 min each on a rotating platform followed
by brief centrifugation. After the final wash, DNA was ex-
tracted by incubating the beads for 15 min with 200 μl
elution buffer (1 % SDS and 50 mM NaHCO3). Samples
were then uncrosslinked in a 65 °C water bath overnight,
and DNA was purified using Qiagen Nucleotide Removal
Kit (Qiagen, Valencia, CA). Polymerase chain reaction
(PCR) primers used to amplify the MT1-MMP promoter
region were as follows: GTCTCCCGCCCCAAGACCCT
(forward) and GGAACACCACATCGGGGGCG (reverse).
Statistical analysis
All experiments were performed three times and the re-
sults were expressed as mean ± SD. Statistical analysis
was performed by SPSS11.0. T test was used in order to
compare the average values between two populations of
data. A P value of less than 0.05 was considered to indi-
cate statistical significance.
Results
Effects of Matrine on migration and invasion of HPAC and
Capan-1 cells
The effects of Matrine on migration of HPAC and
Capan-1 cells were monitored by monolayer wound
healing assay. Log-phase cells were seeded on six-well
plates, and incubation with complete cell medium alone
or contained with 50 μg/ml Matrine or with 0.5 μg/ml
Docetaxel as indicated time. After wounded by a sterile
200 μl pipette tip, cells that were treated with normal
cell medium migrated clearly. But the cells that were
treated with Matrine or Docetaxel have limited migra-
tion (Fig. 1a, b and Additional file 1: Figure S1). In a
three-dimensional cell migration assay with the transwell
system, the invasion cell numbers of the group that
treated with Matrine or Docetaxel for 10 h were less
than the control group (Fig. 1c). This data indicated that
the migration of HPAC cells was inhibited upon Matrine
treatment via an unknown mechanism.
Effects of Matrine on the expressions of MT1-MMP,
MMP2, MMP9
To explore the possible mechanism of the inhibition ef-
fect of Matrine on HPAC cells migration, we first de-
tected the MT1-MMP expression level, which is the
most important mediator of cell migration and invasion.
RT-PCR was used to detect the expression of MT1-
MMP in HPAC cells upon Matrine treatment. We found
that MT1-MMP expression was decreased significantly
upon Matrine treated cells (Fig. 2). Meanwhile, we de-
tected the level of MT1-MMP protein upon Matrine
Fig. 1 The migration of HPAC cells was inhibited by Matrine. Log-phase cells were treated with normal complete RPMI-1640 alone or contained
with 50 μg/ ml Matrine or 0.05 μg/ ml Docetaxel (a). Data were expressed as mean ± S.E.M from three separated experiments (b). Cell invasion
ability was detected by transwell assay (c). Statistical analyses was performed using the t-test. * (P < 0.05) indicates a significant difference compared
with the control group
Fig. 2 Matrine reduced the mRNA expression of MT1-MMP in HPAC cells. The mRNA expression of MT1-MMP in HPAC cell was analyzed by RT-PCR
(a). The mRNA of GAPDH was used for internal control, that indicated the equal total mRNA. Data were expressed as mean ± S.E.M from three
independent experiments. * (P < 0.05) indicates a significant difference compared with the control group (b)
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creased evidently compared with the control group
(Fig. 4a). We also detected the concentration of MMP2
and MMP9 in cell culture medium by ELISA kits, the
results showed that the concentration of MMP2 and
MMP9 decreased significantly in Matrine treatment
(Fig. 3).Wnt signaling pathway may be involved in the MT1-MMP
down-regulation by Matrine treatment
To further explore the exact mechanism of Matrine
down-regulating MT1-MMP expression, we first investi-
gated the effects of Matrine on the Wnt signaling pathway
related properties. When HPAC cells were treated with
Matrine for indicated time, the expression of Wnt and β-
Catenin decreased significantly, paralleled with MT1-
MMP expression level (Fig. 4a). These results suggested
that the MT1-MMP expression was down regulated by
Matrine maybe via Wnt signaling pathway.Effects of Matrine on MT1-MMP transcription activity via
Wnt signaling pathway
CHIP assay was performed in order to determine the re-
lationship between MT1-MMP transcription activity and
Wnt signaling pathway. HPAC cells were treated with
Matrine for 24 h, β-Catenin antibody was used for
immunoprecipitated with target gene (Fig. 4b). The re-
sults have shown that MT1-MMP transcription activity
decreased evidently compared with control cells, which
demonstrated that Matrine regulated MT1-MMP ex-
pression through Wnt signaling.Fig. 3 Effects of Matrine on the expressions of MMP2 and MMP9 in HPAC cel
MMP2 (a), MMP9 (b) in cell culture supernatant were analysed with ELISA
the control groupDiscussion
Previous researches have indicated that Matrine has the
potential function of inhibiting cancer cell migration,
but the exact mechanism has not been unknown. Here,
we have demonstrated that Matrine inhibited the migra-
tion and invasion of HPAC cells through down-regulation
the Wnt-β-Catenin signaling pathway. In our present
study, we first detected the cytotoxicity of Matrine on
HPAC cell growth. We found that proliferation of HPAC
cells were inhibited upon Matrine treatment, especially at
too high a concentration or for too long a time (Additional
file 2: Figure S2). The results are accordance with the earl-
ier researches [2, 5]. In the next experiments, we have de-
tected the invasion ability of HPAC or Capan-1 cells upon
Matrine treatment through wound healing and transwell
assays. We observed that the migration ability has been
decreased significantly upon Matrine treatment for 24 h.
Docetaxel was used for positive control to monitor the ef-
fect of cell migration inhibition. We found that there is no
statistical significance between Matrine and Docetaxel
treated groups.
Tumor invasion and metastasis were multistage and
multi-factorial process, which were regulated by compli-
cated mechanisms and multiple signaling pathways [18].
Many protein molecules have involved in regulating cancer
cell adhesion, migration and invasion in tumor biology be-
haviors. Matrix metalloproteinases (MMPs) are a family of
zinc-binding proteases that have been shown to contribute
to cancer cell invasion through the ability to degrade ECM
[19, 20]. MT1-MMP (also known as MMP-14) is the first
identified and also the most common member of the MT-
MMP subfamily involved in pericellular proteolysis associ-
ated with cell migration [21, 22].ls. HPAC cells were treated as described previously. The concentrations of
assay. * (p < 0.05) indicates a significant difference compared with
Fig. 4 Effects of Matrine on the expressions of MT1-MMP, Wnt, β-catenin in HPAC cells. HPAC cells were treated as described previously. The
expressions of Wnt, β-catenin and MT1-MMP were detected with western blot. Equal loading proteins were shown with β-actin immunoblot
(a). The transcription activity of MT1-MMP in HPAC cells were detected by CHIP assay (b)
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inhibited the migration and invasion of HPAC cells, we
first detected the expression of MT1-MMP in HPAC
cells upon Matrine treatment. Indeed, we found that the
mRNA and protein expressions of MT1-MMP decreased
evidently upon Matrine treatment.
The activities of most MMPs are very low in the nor-
mal tissues, however their expressions are regulated by
various inflammatory cytokines, growth factors, hor-
mones as well as by cell-cell interaction [23]. Moreover,
the proteolytic activity of MMPs is strictly controlled at
several levels, including transcriptional, posttranscriptional
and post-translational, as well as via their endogenous in-
hibitors [24, 25]. The transcription of MT1-MMP was
regulated by Wnt signaling pathway [26, 27], so we hy-
pothesized that Matrine inhibited HPAC migration and
invasion may be through down-regulation the Wnt sig-
naling pathway. According to this assumption, we de-
tected the expressions of Wnt and β-Catenin. Western
blotting assay indicated that the expressions of Wnt
and β-Catenin decreased markedly compared to the
control group. However, the positive control, that the
docetaxel treated group, their expressions decreased
weakly. These results suggested that Matrine has a po-
tential role in down-regulating the expressions of Wnt
and β-Catenin. To investigate the transcription activity
of MT1-MMP whether mediated by the Matrine treat-
ment through Wnt signaling pathway, we detected the
MT1-MMP transcription activity through CHIP assay.
As our expected, upon Matrine treatment, a small
amount of MT1-MMP was detected, decreased signifi-
cantly compared with the control group.
In summary, our present data first demonstrated that
Matrine play a potential role in inhibiting the migration
and invasion of HPAC cells, which may be through down-
regulation the expression of MT1-MMP via the canonical
Wnt signaling pathway. It is interesting that Matrine
down-regulation the expression of MT1-MMP, which is
identified as an activator of proMMP-2 (pro-gelatinaseA/72 kDa type IV collagenase) [28]. Since the degrad-
ation of the basement membrane by MMP-2 is likely a
necessary step for cancer invasion [29, 30]. It is neces-
sary to research whether Matrine mediated the activity
of other MMPs, which is the next question we need to
identify.Additional files
Additional file 1: Figure S1. Regulation of cell migration by Matrine in
Capan-1 cells.
Additional file 2: Figure S2. Regulation of cell proliferation by Matrine in
HPAC or Capan-1 cells. Log-phase cells were treated with normal complete
RPMI-1640 medium contained with various concentrations Marine for
indicated time. Cell proliferation was detected with MTT assay. Data
were expressed as mean ± S.E.M from three separate experiments. Statistical
analysis was performed using the t-test. *(P < 0.05) indicates a significant
difference compared with the control group.Abbreviations
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